Zelmac (Novartis AG).
Novartis is developing Zelmac (SDZ-HTF-919), a 5-HT4 receptor partial agonist, which is in phase III clinical trials for the treatment of gastric motility disorders and irritable bowel syndrome (IBS). Warburg Dillon Read estimated (in January 1999) that Zelmac will achieve sales of 240 million Swiss Francs in 2001.